First Financial Bankshares Inc Grows Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

First Financial Bankshares Inc lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,280 shares of the medical equipment provider’s stock after purchasing an additional 34 shares during the period. First Financial Bankshares Inc’s holdings in Intuitive Surgical were worth $3,278,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ISRG. Atala Financial Inc purchased a new stake in Intuitive Surgical in the fourth quarter worth $25,000. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical during the 4th quarter worth $26,000. BankPlus Trust Department bought a new position in shares of Intuitive Surgical during the 4th quarter worth $28,000. Kohmann Bosshard Financial Services LLC bought a new stake in Intuitive Surgical in the 4th quarter valued at about $31,000. Finally, MidAtlantic Capital Management Inc. bought a new stake in Intuitive Surgical in the 3rd quarter valued at about $33,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

ISRG stock opened at $483.95 on Wednesday. The firm has a 50 day simple moving average of $565.43 and a two-hundred day simple moving average of $531.90. The stock has a market cap of $172.37 billion, a PE ratio of 75.50, a P/E/G ratio of 5.85 and a beta of 1.43. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00.

Insider Buying and Selling

In related news, EVP Brian Edward Miller sold 8,900 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the sale, the executive vice president now owns 5,758 shares in the company, valued at $2,793,033.06. The trade was a 60.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the transaction, the director now owns 12,275 shares in the company, valued at $6,955,015. The trade was a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,754 shares of company stock worth $17,691,621. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ISRG shares. BTIG Research lifted their target price on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Royal Bank of Canada lifted their price objective on shares of Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. Barclays boosted their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. Truist Financial cut their price target on Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating for the company in a report on Monday. Finally, Evercore ISI boosted their price objective on Intuitive Surgical from $490.00 to $530.00 in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $611.86.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.